AbbVie spikes as Q1 beat prompts guidance raise

AbbVie rises as it beats Wall Street estimates, raises 2025 outlook

The success was driven by better-than-expected sales of its newer autoimmune medicines that have made up for the fading revenue from its blockbuster drug Humira, which had its patent expire in 2023.

AbbVie spikes as Q1 beat prompts guidance raise

AbbVie: Q1 Earnings Snapshot

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported first-quarter profit of $1.29 billion.

A Pharmaceutical Giant Surges: AbbVie's Financial Spectacle Stuns Wall Street

AbbVie surpassed quarterly earnings expectations, driving a 3.10% stock increase, significantly outpacing the 0.6% rise of the S&P 500 index. Net revenues in Q1 reached $13.3 billion, reflecting an 8% increase, primarily driven by the success of Skyrizi and Rinvoq, which generated nearly $6.3 billion. Despite a slight decrease in net income to $1.29 billion, results exceeded analyst predictions, which forecasted $12.9 billion in revenue and $2.3…

AbbVie's Strong Q3 Results Boost Stock - PressReach

AbbVie Inc. (NYSE:ABBV) recently reported financial results for the third quarter, which exceeded market expectations and provided an optimistic outlook for the remainder of the year. The company’s stock experienced a notable increase as investors reacted positively to the news. In the third quarter, AbbVie reported earnings per share (EPS) that surpassed analysts’ forecasts, largely driven by strong performance from its immunology and oncology …

AbbVie Q1 2025 Adjusted Earnings Increase On 8% Revenue Growth; Beat Estimates

Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the March quarter, up 8% from the corresponding period of 2024. The main operating segments registered growth. Net income, adjusted for special items, rose to $2.46 per share in Q1 from $2.31 per share in the year-ago quarter, e…